Form 4: uniQure Director Leonard Post Reports Equity Transactions

Director Leonard E. Post acquired restricted share units and exercised stock options, with a portion sold to cover tax obligations.

Summary

• Director Leonard E. Post received a grant of 7,550 restricted share units (RSUs) on June 10, 2026.
• The Director was granted 13,980 stock options with an exercise price of $26.82 on June 10, 2026.
• A total of 1,993 shares were sold on June 11, 2026, at a weighted average price of $27.06 to satisfy tax withholding requirements.
• Following these transactions, the Director holds 35,494 ordinary shares and 13,980 stock options.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard director compensation and tax compliance.

Positives

• Director maintains a significant equity stake of 35,494 shares, aligning interests with shareholders.
• The sale of shares was non-discretionary, executed solely to cover tax withholding obligations related to RSU vesting.

Negatives

• The sale of 1,993 shares, while mandatory for tax purposes, reduces the total direct share count.

Risks

• Vesting of equity awards is contingent upon the Director's continued relationship with the issuer.

Future Outlook

The equity grants vest 100% on the first anniversary of the grant date (June 10, 2027), subject to continued service.

Management Comments

• The sale was not a discretionary trade by the Reporting Person.

Industry Context

StockSavvy.ai notes that routine equity grants and tax-related sales by directors are standard corporate governance practices in the biotechnology sector, reflecting typical compensation structures rather than shifts in strategic outlook.

Comparison to Industry Standards

• The use of automatic sell-to-cover transactions for tax obligations is a standard practice among publicly traded biotech firms to manage insider tax liabilities.
• The one-year cliff vesting schedule for equity awards is consistent with industry norms for board compensation.

Stakeholder Impact

• Minimal impact on shareholders as the transactions were related to standard compensation and tax obligations.

Next Steps

• Vesting of restricted share units on June 10, 2027.
• Vesting of stock options on June 10, 2027.

Key Dates

Keywords

uniQure, QURE, Form 4, Insider Trading, Equity Compensation, Biotech